Kymab nabs £20mm from Wellcome Trust for Series A round
Wellcome Trust has provided monoclonal antibody developer Kymab Ltd. with £20mm ($30mm) in Series A financing. The start-up spun off from the Wellcome Trust Sanger Institute last year.
- Synthesis Technologies, Production Processes
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.